{"id":"W3015984203","doi":"10.1182/blood.2019004143","title":"Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta Hospital; Health Sciences Centre; Alberta Hospital Edmonton; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Astex Pharmaceuticals","keywords":"Decitabine; Medicine; Neutropenia; Chronic myelomonocytic leukemia; Febrile neutropenia; Internal medicine; Adverse effect; Confidence interval; Gastroenterology; Pharmacodynamics; Azacitidine; Pharmacology; Myelodysplastic syndromes; Pharmacokinetics; Toxicity; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00295441,0.002809136,0.004313262,0.0008893319,0.0006006508,0.001101348,0.001330971,0.001976822,0.006368638],"category_scores_gemma":[0.001979158,0.001326244,0.001576803,0.000684826,0.001492256,0.001500273,0.000628291,0.003400484,0.001010123],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001120429,"about_ca_system_score_gemma":0.001817242,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006625752,"about_ca_topic_score_gemma":0.001239489,"domain_scores_codex":[0.9988085,0.0006454676,0.00005715825,0.0001878594,0.0001027854,0.0001983206],"domain_scores_gemma":[0.9986001,0.0003032019,0.0003027775,0.0001760135,0.00008678104,0.0005311742],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9175868,0.05403613,0.0006634312,0.0003043762,0.0003523348,0.00006801409,0.0000852856,0.0005992325,0.01152207,0.0001336438,0.0005905124,0.01405824],"study_design_scores_gemma":[0.7414681,0.2544642,0.001350295,0.00001385796,0.0001497415,0.00005271225,0.00001686545,0.0004791769,0.001101207,0.0001158078,0.0007688779,0.00001911543],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9875502,0.001161647,0.001031809,0.0003893114,0.0002334262,0.007723186,0.0008754646,0.0001242018,0.0009107507],"genre_scores_gemma":[0.9702206,0.001740585,0.004746504,0.001181061,0.0007096758,0.01589865,0.001501059,0.00006392305,0.003937851],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006368638,"threshold_uncertainty_score":0.0213052,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03744326903252199,"score_gpt":0.3788024146390228,"score_spread":0.3413591456065008,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}